February 27, 2018 09:51 AM EST

Exelixis/Daiichi Sankyo ask Japanese regulators for green light on hypertension drug; Bristol-Myers Squibb licenses GPCR tech from Domain Therapeutics

Amber Tong

→ San Francisco’s Exelixis $EXEL — and its partner Daiichi Sankyo — has asked Japanese regulators for the OK to sell their investigational hypertension drug called …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exelixis/Daiichi Sankyo ask Japanese regulators for green light on hypertension drug; Bristol-Myers Squibb licenses GPCR tech from Domain Therapeutics

Amber Tong

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Ex­elix­is/Dai­ichi Sankyo ask Japan­ese reg­u­la­tors for green light on hy­per­ten­sion drug; Bris­tol-My­ers Squibb li­cens­es GPCR tech from Do­main Ther­a­peu­tics

Amber Tong

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Exelixis/Daiichi Sankyo ask Japanese regulators for green light on hypertension drug; Bristol-Myers Squibb licenses GPCR tech from Domain Therapeutics

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Bristol Myers reveals more job cuts in New Jersey

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA